Participation in the European Rheumatology Congress
Celltrion Group announced on the 2nd that it held an academic symposium titled "From Infliximab IV to SC? Major Therapeutics for Rheumatic Diseases" at the European League Against Rheumatism Congress held at the MiCo Convention Center in Milan, Italy, on the 1st (local time).
On the 1st (local time), Celltrion Group held an academic symposium titled "From Infliximab IV to SC? Major Therapeutics for Rheumatic Diseases" at the European League Against Rheumatism conference held at the MiCo Convention Center in Milan, Italy. Photo from the symposium venue. [Photo by Celltrion]
More than 200 rheumatic disease specialists and industry stakeholders from around the world attended the symposium. At the symposium, Celltrion Group highlighted Remsima and Remsima SC as major therapeutics for rheumatic diseases. Remsima is a biosimilar of Johnson & Johnson's autoimmune disease treatment Remicade (generic name infliximab).
Attendees focused on the competitiveness of Remsima SC, the subcutaneous (SC) formulation. Celltrion explained that Remsima SC, the first SC formulation of infliximab, demonstrated superiority in clinical trials involving rheumatoid arthritis patients compared to the existing intravenous (IV) infliximab formulation. It also emphasized that efficacy and safety were confirmed in clinical trials involving patients with ankylosing spondylitis (AS), a major indication for infliximab.
Celltrion Group also introduced that following Remsima, Remsima SC?with its convenience and efficacy?has been launched in the market, and both products are gaining attention as major therapeutics for rheumatic diseases.
A Celltrion Group representative said, "With the statistical superiority of Remsima SC over infliximab IV confirmed in clinical trials involving rheumatoid arthritis patients, the competitiveness of Remsima SC is gaining more attention. Following Remsima, which has secured a leading position in the industry with a stable market share in Europe, we will do our best to expand the supply of Remsima SC, which offers patient convenience, as an effective treatment option in Europe and the global market."
Meanwhile, Remsima and Remsima SC recorded a combined market share of 60.6% in the European market as of the fourth quarter of last year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
